Warfarin sensitivity after mechanical heart valve replacement

Pharmacotherapy

Volumn 18, Issue 4, 1998, Pages 856-859

  Rose, John P ^a   Rihn, Thomas L ^b   Long, Scott F ^b  

^a ALLEGHENY UNIVERSITY HOSPITALS   (United States)

^b DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ANTICOAGULATION; ARTICLE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG INDICATION; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN TIME; RETROSPECTIVE STUDIES; WARFARIN;

EID: 0031827192     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(4 suppl):231S-46.
2. Erdman SM, Rodvold KA, Friedenberg WR. Thromboembolic disorders. In: DiPiro JT, Talbert RL, Hayes PE, Yee GC, Matzke GR, eds. Pharmacotherapy: a pathophysiologic approach, 2nd ed. Norwalk, CT: Appleton & Lange, 1993:322-7.
3. Doyle AR, Dhir AK, Moors AH, et al. Treatment of perioperative low cardiac output syndrome. Ann Thorac Surg 1995;59:S3-11.
4. Bachmann F, McKenna R, Cole ER, et al. The hemostatic mechanism after open-heart surgery. J Thorac Cardiovasc Surg 1975;70:76-85.
5. Gralnick HR, Fischer RD. The hemostatic response to open-heart operations. J Thorac Cardiovasc Surg 1971;61:909-15.
6. Kalter RD; Saul CM, Wetstein L, et al. Cardiopulmonary bypass: associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979;77:427-35.
7. Hakanson E, Svedjeholm R, Vanhanen I. Physiologic aspects in postoperative cardiac patients. Ann Thorac Surg 1995;59(2 suppl):S12-14.
8. Killilea TA, Eugene OR, White R, et al. Increased response to warfarin in valve-replacement patients compared to PE/DVT patients [abstr]. Clin Pharmacol Ther 1988;43:161.
9. O'Neill CK, Rihn TL. Warfarin dosing requirements following prosthetic valve replacement [abstr]. Int Pharm Abstr 1989;24:350.
10. Jandel Corp. SigmaPlot, version 2.0. San Rafael, CA: Author, 1994.
11. Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulation therapy. Am J Med 1987;82:703-13.
12. Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulation therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991;101:427-31.
13. Saour JN, Sieck JO, Mamo LAR, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990;322:428-32.